XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,484 $ 2,336
Available-for-sale investments 80,070 105,575
Other receivables 426 435
Prepaid expenses 4,375 5,223
Total current assets 93,355 113,569
Restricted cash 733  
Property and equipment, net 558 543
Operating lease, right-of-use assets 827 1,267
Financing lease, right-of-use assets 368  
Other assets 175 158
Total assets 96,016 115,537
Current liabilities:    
Accounts payable 1,674 1,031
Accrued expenses 6,610 4,002
Current portion of operating lease liability 906 980
Current portion of financing lease liability 70  
Total current liabilities 9,260 6,013
Long-term operating lease liability, net of current portion   398
Long-term financing lease liability, net of current portion 298  
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of June 30, 2022 (unaudited) and December 31, 2021; Class X Convertible Preferred Stock, issued and outstanding shares - 0 as of June 30, 2022 (unaudited) and December 31, 2021
Common stock, $0.001 par value per share; 85,000,000 and 42,500,000 authorized shares as of June 30, 2022 (unaudited) and December 31, 2021, respectively; issued and outstanding shares - 28,127,458 and 27,793,035 as of June 30, 2022 (unaudited) and December 31, 2021, respectively 28 28
Additional paid-in capital 484,286 481,832
Accumulated other comprehensive loss (810) (263)
Accumulated deficit (396,869) (372,296)
Total aTyr Pharma, Inc. stockholders’ equity 86,635 109,301
Noncontrolling interest in Pangu BioPharma Limited (177) (175)
Total stockholders’ equity 86,458 109,126
Total liabilities and stockholders’ equity $ 96,016 $ 115,537